San Diego, CA - Modulo Bio, a pioneering biotechnology company dedicated to reprogramming the brain's immune system to combat neurodegenerative disorders, announced today the successful completion of a funding round, raising an impressive $8,000,000. The round was led by prominent venture capital firms, Builders VC and Initialized Capital, alongside participation from Cantos, Refactor Capital, Spacecadet, and Bioverge Ventures.

Neurodegenerative disorders affect more than 1 billion individuals and their families worldwide, causing immense emotional and physical distress. Modulo Bio's mission is to discover groundbreaking treatments that leverage the potential of the neuroimmune system, offering new hope to patients suffering from these debilitating conditions.

"We are thrilled to have secured $8 million in funding, which will enable us to accelerate our research and development efforts," said Michael Horowitz, Co-Founder of Modulo Bio. "This investment will help us further our mission of revolutionizing neurodegenerative disorder treatments, bringing relief to millions of individuals and their loved ones."